1. Scrip
  2. >>Therapy Areas

Jardiance's Label Expansion Will Change Diabetes Management

US approval of the first cardiovascular label expansion for an anti-diabetic medicine will mark a shift in disease management, says Datamonitor Healthcare analyst Kevin Shannon.

The US FDA approved the first cardiovascular (CV) label expansion for an anti-diabetic, Jardiance (empagliflozin; Boehringer Ingelheim GMBH/Eli Lilly & Co.), on December 2, 2016. The drug is now approved to "reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease". (Also see "BI/Lilly's Jardiance Is First Diabetes Drug With CV Benefit Claim" - Scrip, 2 December, 2016.)

Jardiance's CV benefit and the resulting label addition are expected drive significant uptake of the drug in the diabetes market....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapy Areas

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.